35,25 $
0,11 %
Nasdaq, 22. Februar, 22:15 Uhr
ISIN
US30233M1071
Symbol
EYEG
Berichte
Sektor
Industrie

EyeGate Pharmaceuticals, Inc. Aktie News

Positiv
ETF Trends
2 Monate alt
On the heels of crossing the $1 billion threshold in active ETF AUM, AllianceBernstein has launched five active exchange-traded funds today: two on the New York Stock Exchange, and three on the Nasdaq.
Neutral
PRNewsWire
3 Monate alt
Lineup includes one Buffered product and four Fixed Income products in AB's ETF suite NASHVILLE, Tenn. , Dec. 13, 2023 /PRNewswire/ -- AllianceBernstein Holding L.P.
Positiv
Pulse2
mehr als 2 Jahre alt
The stock price of Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) increased 22.95% in the previous trading session. This is why it happened.
Positiv
PennyStocks
mehr als 2 Jahre alt
Investing in penny stocks in 2021? Check these three out for next months watchlist The post Best Penny Stocks to Buy Right Now?
Neutral
GlobeNewsWire
mehr als 2 Jahre alt
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate's President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in on...
Neutral
GlobeNewsWire
mehr als 2 Jahre alt
-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-
Neutral
GlobeNewsWire
mehr als 2 Jahre alt
WALTHAM, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today reported its financial results for the quarter ended June 30, 2021 and provided an update on recent...
Neutral
GlobeNewsWire
mehr als 2 Jahre alt
WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and certain systemic diseases, today announced the closing of its previously announced registered direct offering priced at-the-marked un...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen